ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
bearishWuxi Biologics
14 Jan 2019 04:16

WuXi Biologics – The Foxconn or Qualcomm of Global CDMO?

During the first week of 2019, we visited Wuxi Biologics (Cayman) Inc (2269 HK) headquarters in Shanghai, as well as spend time touring the lab....

Logo
846 Views
Share
bearishWuXi AppTec
11 Dec 2018 19:57

WuXi AppTec IPO Valuation: Bull/​Bear Case DCF Scenarios

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
512 Views
Share
30 Nov 2018 05:53

G20 Game of Roulette:  Where Will Trump-Xi Ball Land? + 2018 Holiday Season Conviction Shorts

From conversations with investors, we believe that the market strongly expects a “positive” outcome whereby the US agrees to freeze the trade...

Logo
429 Views
Share
bearishWuXi AppTec
20 Nov 2018 20:34

WuXi AppTech IPO Trading Update: What’s up with the Poor Cash Conversion?

WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
888 Views
Share
bullishWuXi AppTec
19 Nov 2018 06:57

WuXi AppTech IPO Preview: Pharmed Out

WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Logo
1.1k Views
Share
x